Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid-stage ...

The combination of Regeneron's drug, trevogrumab, and Wegovy helped preserve up to 51.3% of the lean mass after 26 weeks, compared with 34.5% loss when Wegovy was administered alone, according to ...

(Reuters) -Regeneron Pharmaceuticals said on Monday its experimental weight-loss drug combination helped preserve muscle mass in a mid-stage study. The drug candidate, trevogrumab, in combination ...

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

The combination offers a potential solution to one of the key problems that’s emerged with popular obesity shots.

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.

A new study finds combining bimagrumab with Wegovy leads to significant fat loss without muscle loss. This breakthrough ...

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...